The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Waldenstrom Macroglobulinemia

Rare lymphoplasmacytic lymphoma producing monoclonal IgM with hyperviscosity, neuropathy, and bone marrow infiltration.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is Waldenstrom Macroglobulinemia?

Waldenstrom macroglobulinemia (WM) is an indolent B-cell lymphoma classified as lymphoplasmacytic lymphoma with bone marrow involvement and a serum monoclonal IgM paraprotein. It accounts for less than 2% of hematologic malignancies, with a median age at diagnosis of 65–70 years and a slight male predominance.

Over 90% of WM cases harbor the MYD88 L265P somatic mutation that activates NF-kB signaling and serves as a diagnostic and therapeutic marker. Approximately 30–40% also carry CXCR4 mutations that influence response to BTK inhibitors. Clinical features arise from bone marrow infiltration (cytopenias), monoclonal IgM (hyperviscosity, cryoglobulinemia, cold agglutinin disease, IgM-related neuropathy), and tissue infiltration (hepatosplenomegaly, lymphadenopathy).

Diagnosis requires bone marrow biopsy showing greater than 10% lymphoplasmacytic infiltrate, monoclonal IgM, and MYD88 L265P. Asymptomatic patients are observed; treatment is initiated for hyperviscosity, cytopenias, neuropathy, organomegaly, or constitutional symptoms. First-line regimens include BTK inhibitors (ibrutinib, zanubrutinib), bendamustine plus rituximab, or proteasome inhibitor combinations. Plasmapheresis is used emergently for hyperviscosity syndrome.

Symptoms

Fatigue from anemia
Hyperviscosity (headache, blurred vision, epistaxis, mucosal bleeding)
Peripheral neuropathy (sensory ataxia, paresthesias)
Lymphadenopathy
Hepatosplenomegaly
Recurrent infections
Raynaud phenomenon (cryoglobulinemia)
Cold agglutinin hemolytic anemia
Bing-Neel syndrome (CNS infiltration)
Weight loss, night sweats
Easy bruising, bleeding
Visual disturbances, retinal hemorrhages
Skin nodules, plaques
Renal involvement (rare)
Asymptomatic monoclonal IgM (smoldering WM)

Risk Factors

Age over 60
Male sex
Family history of WM or other B-cell malignancy
MYD88 L265P somatic mutation (>90%)
CXCR4 mutation (~30%)
IgM monoclonal gammopathy of undetermined significance (IgM-MGUS) precursor
Hepatitis C infection (debated)
Autoimmune disorders (Sjögren, hemolytic anemia)
Caucasian ethnicity
Ashkenazi Jewish heritage (slight increase)
Prior radiation exposure
Pesticide, hair dye exposure (debated)
Smoking (weak association)
First-degree relative with B-cell lymphoma
Idiopathic in most

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Unexplained anemia or pancytopenia
  • Hyperviscosity symptoms (headache, vision changes, epistaxis)
  • Progressive sensory neuropathy
  • Persistent lymphadenopathy or splenomegaly
  • Cold-induced symptoms (Raynaud, hemolysis)
  • Recurrent unexplained infections
  • Monoclonal IgM on protein electrophoresis
  • Constitutional symptoms (weight loss, night sweats)
  • CNS symptoms suggestive of Bing-Neel syndrome
  • Family history of WM or IgM-MGUS

Treatment Methods

01
Serum protein electrophoresis with immunofixation to identify monoclonal IgM
02
Quantitative serum IgM, beta-2 microglobulin, viscosity testing
03
Bone marrow aspirate, trephine biopsy with flow cytometry and immunohistochemistry
04
MYD88 L265P testing by allele-specific PCR; CXCR4 mutation analysis
05
CT chest/abdomen/pelvis for organomegaly and lymphadenopathy
06
Cryoglobulin and cold agglutinin testing
07
Anti-MAG antibody and electrodiagnostic studies if neuropathy
08
Watch and wait for asymptomatic disease
09
Plasmapheresis for symptomatic hyperviscosity
10
Ibrutinib monotherapy (especially MYD88 mutated, CXCR4 wild-type)
11
Zanubrutinib (better tolerability profile)
12
Bendamustine plus rituximab (BR) for fit patients
13
Bortezomib, dexamethasone, rituximab (BDR) particularly with hyperviscosity
14
Rituximab monotherapy for IgM-related neuropathy or older frail patients
15
Avoid rituximab monotherapy if IgM > 4000 mg/dL (IgM flare risk)
16
Autologous stem cell transplantation in selected relapsed cases
17
Antiviral and PJP prophylaxis during BTK inhibitor or chemoimmunotherapy
18
Long-term hematology follow-up with serial IgM measurement
19
Patient education on hyperviscosity warning signs and bleeding risk

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.